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a b s t r a c t
A DNA vaccine expressing dengue-4 virus premembrane (prM) and envelope (E) genes was produced by
inserting these genes into a mammalian expression plasmid (pCI).
Following a thorough screening, including conﬁrmation of protein expression in vitro, a recombinant
clone expressing these genes was selected and used to immunize BALB/c mice. After 3 immunizations all
the animals produced detectable levels of neutralizing antibodies against dengue-4 virus. The cytokineseywords:
engue-4
ecombinant DNA
accine
lasmid
levels and T cell proliferation, detected ex vivo from the spleen of the immunized mice, showed that our
construction induced substantial immune stimulation after three doses. Even though the antibody levels,
induced by our DNA vaccine, were lower than those obtained in mice immunized with dengue-4 virus
the levels of protection were high with this vaccine.
Thisobservation is further supportedby the fact that80%of thevaccine immunizedgroupwasprotected
n con
viruagainst lethal challenge. I
E proteins from dengue-4
. Introduction
Dengue virus (DENV) infections are often asymptomatic, but
hey can also produce a mild self-limiting acute febrile illness
enominated dengue fever (DF), and a life threatening severe
llness, which may present with minor or major bleeding from dif-
erent sites (dengue hemorrhagic fever/dengue shock syndrome
DHF/DSS]). There are four serotypes of dengue viruses (DENV-1,
ENV-2, DENV-3, andDENV-4), and sequential infections by differ-
nt serotypes have been implicated in the causation of DHF/DDS,
lthough it is not an exclusive determinant of severe disease [1].
The global pandemic of dengue fever (DF) has intensiﬁed in
he last decade, accompanied by a concurrent rise in the num-
er of cases of the disease’s most severe manifestations (DHF/DSS).
engue virus infections are a steadily worsening health problem in
ropical regionsof theworld,with approximatelyhalf of theworld’s
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línica Médica, Faculdade de Medicina de Ribeirão Preto – Universidade de São
aulo, Avenida dos Bandeirantes, 3900 Ribeirão Preto, CEP: 14049-900, São Paulo,
razil. Tel.: +55 16 3602 3249; fax: +55 16 3602 4547.
E-mail address: baldfons@fmrp.usp.br (B.A.L.d. Fonseca).
264-410X © 2010 Elsevier Ltd. 
oi:10.1016/j.vaccine.2010.10.078
Open access under the Elsevier OA license.clusion, we developed a DNA vaccine employing the genes of the prM and
s that protects mice against this virus.
© 2010 Elsevier Ltd. 
population residing in dengue endemic regions, where more than
100 million cases of DF and hundreds of thousands of cases of
DHF/DSS are reported to the World Health Organization each year
[2,3]. There is no treatment for this disease and immunization
may provide the only realistic approach for controlling dengue
infections. However, since DHF/DSS have been associatedwith sec-
ondary dengue virus infections, a vaccine candidate must elicit
antibodies against all four dengue serotypes to provide safe pro-
tection against dengue [4]. Six decades of effort have been invested
in the development a dengue vaccine, in part to allay fears that
immunization may predispose individuals to severe disease. DNA
vaccines have been shown to present dengue antigens efﬁciently
as they have induced both antibody and T-cell responses, as well
as protective immunity, in numerous animal models [5]. Currently,
there are no licensed vaccines for dengue since vaccine develop-
ment has been hampered thus far by the lack of an animal model
for DF or DHF/DSS, and the perceived need for a protective immune
response to all four serotypes of dengue virus concurrently [2].
Open access under the Elsevier OA license.The most promising candidates are live attenuated, made by
serial passage of wild-type virus isolates in primary cell cul-
tures, and live attenuated chimeric virus vaccines [6–11]. These
candidates are well advanced into clinical trials and have pro-
duced favorable results [12–15]. However, optimization of vaccine
8 ccine 29 (2011) 831–838
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Table 1
Primers employed to sequence the recombinant plasmids.a
Primer name Sequence
PCI sense 1 5′-CAC TAT AGG CTA GCC TGC AG-3′
DEN-4 AS1 5′-CCG CTC TGG GTG CAT GTC CC-3′
DEN-4 sense2 5′-GGG ACA TGC ACC CAG AGC GG-3′
DEN-4 AS2 5′-AGG TCG ACC CAT GCT CCA CC-3′
DEN-4 sense3 5′-GGT GGA GCA TGG GTC GAC CT-3′
DEN-4 AS3 5′-GCA CAT GTC ACA ACT CCT CC-3′
DEN-4 sense4 5′-GGA GGA GTT GTGACA TGT GC-3′
DEN-4 AS4 5′-GCT GTC CAT GGA AGA GGC AG-3′
DEN-4 sense5 5′-CTG CCT CTT CCA TGG ACA GC-3′
DEN-4 AS5 5′-ATC ACT ATG TAG CTG TCC CC 3′
DEN-4 sense 6 5′-GGG GAC AGC TAC ATA GTG AT-3′32 D.M. Lima et al. / Va
mmunogenicity and virus attenuation have been difﬁcult to
chieve, and there may be interference among the virus serotypes
ith some tetravalent DNA vaccine formulations [7,14]. Evidence
or cross serotype interference has been detected in rhesus mon-
eys [16].
Nucleic acid immunization is a novel approach that is capable
f eliciting strong cellular and humoral immune responses, and
hus, it could be potentially employed for the development of a
etravalent dengue vaccine [17].
A new vaccination strategy for DENV was evaluated by priming
hesus macaques either with a tetravalent mixture of inactivated
iruses or a tetravalent plasmid DNA vaccine expressing the struc-
ural prM/E gene region followed by boosting 2 months later with
tetravalent live attenuated virus vaccine. After challenge with
ach one of the four DENV serotypes, vaccinated animals exhib-
ted no viremia but showed anamnestic antibody responses to the
hallenge viruses [18]. However, only a few dengue DNA vaccine
andidates, inparticular forDENV-4, havebeen reported [11,19,20].
n this studywe constructed a DNA vaccine expressing the prM and
genes of dengue-4 virus, using pCI as vector. After construction
nd characterization of the recombinant plasmids in vitro, the pro-
ection against challenge offered by this vaccine was evaluated in
ice. The results shown here conﬁrm that the DENV-4 DNA vac-
ine (DENV-4-DNAv), produced in this study, is very immunogenic
liciting production of neutralizing antibodies and good levels of
rotection after challenge.We conclude that this vaccine is a strong
andidate to be included in a tetravalent formulation of a DNA-
ectored dengue vaccine.
. Materials and methods
.1. Cell lines, virus and plasmids
C6/36, Vero and HeLa cells were purchased from the Cell Cul-
ure Section of Adolfo Lutz Institute, São Paulo, Brazil. DENV-4
irus (DENV-4 H241 strain [GenBank sequence accession number
Y947539.1]) was kindly donated by Dr. Robert E. Shope, Univer-
ity of Texas atGalveston, TXandused throughout the experiments.
he expression plasmid (pCI) was purchased from Promega Corpo-
ation, Madison, WI.
.2. Recombinant plasmid (DENV-4-DNAv) construction
C6/36 cells were grown at 28 ◦C in L15 Leibovitz medium
Life Technologies, Gaithersburg, MD) supplemented with 10% of
etal bovine serum (FBS) and antibiotics. Conﬂuent monolayers of
6/36 cells were infected with dengue-4 virus, H-241 strain, and
ncubated at 28 ◦C in maintenance medium (2% FBS). The percent-
ge of dengue-4 infected cells was daily assayed by an indirect
mmunoﬂuorescenceassay (IFA)usinghyperimmunemouseascitic
uid (MIAF). When IFA showed 100% of infected cells, the RNA
as extracted using TRIzol® (Life Technologies) according to the
anufacturer’s protocol, and the RNA was then used as a tem-
late to amplify the DENV-4 prM and E protein genes by RT-PCR.
o amplify the viral genome the RNA was reverse transcribed in
standard reaction using a random hexamer primer (pdN6) and
uperscript II Mix (Invitrogen, New York, USA). In order to man-
facture the prM and E genes of DENV-4 virus we used speciﬁc
rimer. In this PCR reaction we used a positive strand primer
5′-CCCGAATTCTGAACGGGAGAAAAAGGT-3′), which introduced a
′-end EcoRI cleavage site (bold letters) and a negative strand
rimer (5′-GGGGGTACCATTCTGCTTGAACTGTGAAGC-3′) providing
Kpn I recognition sequence at the 3′end and a stop codon fol-
owing the last codon in the E protein gene, we used Platinum®
aq DNA Polimerase (Invitrogen) for ampliﬁcation. These primersPCI AS6 5′-ATC ATG TCT GCT CGA AGC GG-3′
a All primer sequences were deﬁned based on DENV-4 strain H241 available at
GenBank.
were created on basis of the sequence of dengue-4 virus avail-
able at GenBank (accession number AY947539.1). To generate a
recombinant plasmid expressing the dengue-4 virus genes the
ampliﬁed fragment and the pCI plasmidwere sequentially digested
with EcoRI and Kpn I restriction enzymes, puriﬁed through gel
electrophoresis and ligatedwithT4DNA ligase (Invitrogen), follow-
ing manufacturer’s instructions. The recombinant plasmids were
transformed by heat shock protocol in competent Escherichia coli
DH5. Following screening of a large number of recombinants, a
recombinant clone containing the insert positioned correctly on
the plasmid, which was conﬁrmed by sequencing of the construct,
was selected as a vaccine candidate. This clone was denominated
DENV-4-DNAv.
2.3. Nucleotide sequencing of plasmids expressing prM/E proteins
Sequencing primers were designed using the DENV-4 H241
strain sequence (GenBank accession number AY947539.1) as
genome reference. For whole-region sequencing, PCR primer pairs
were listed above.
The selected clones were grown at 37 ◦C in LB medium with
ampicillin 100g/ml. These plasmids were extracted using the
GeneJET Plasmid Miniprep Kit (Fermentas Life Sciences, USA),
quantiﬁed by UV absorption (260nm) and approximately 500ng of
each plasmid was sequenced using the ABI Prism Big Dye Termina-
tor Cycle Sequencing Ready Kit and the primers listed on Table 1.
The obtained sequences were aligned and a ﬁnal manual adjust-
ment was completed with BioEdit software. These sequences were
then compared with the sequence available at the Genbank.
2.4. Plasmid transfection for protein expression analysis of
DENV-4-DNAv
The expression of dengue-4 E protein by DENV-4-DNAv was
analyzed by transfecting HeLa cells with the candidate vaccine
using cationic lipid-based delivery. In summary, 50g of plas-
mid DNA was mixed with the cationic lipid LipofectamineTM 2000
(Invitrogen) at a lipid/DNA mass ratio of 2:1 in 1ml of L15-FBS
free for 45min at room temperature. The mixture was added
to cells grown to approximately 80% of conﬂuence in 35-mm
dishes (Costar, Cambridge, MA) and incubated at 37 ◦C in a 5%
CO2 incubator. After 12h of incubation, an additional 2ml of
L15 medium with 10% FBS were added to the cells. Seventy-two
hours after transfection, the cells were washed by centrifuga-
tion with phosphate-buffered saline (PBS), resuspended in cell
lysis buffer (20mM Tris–HCl (pH 7.5), 150mM NaCl, 1mM Na2
EDTA, 1mMEGTA, 1% Triton, 2.5mMsodiumpyrophosphate, 1mM
b-glycerophosphate, 1mM Na3VO4, 1g/ml leupeptin) and son-
icated brieﬂy. As positive control we infected HeLa cells with
ccine
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ive dengue-4 virus (M.O.I = 1). After 3 days of incubation the
ells were analyzed by indirect immunoﬂuorescence (IFA) to
etect protein expression, another fraction of the cellular extracts
ere subsequently analyzed by immunoprecipitation followed by
estern blot.
.5. Immunoprecipitation and western blot
Cellular extractswereprepared fromtransfectedHeLa cells after
he labeling period as described. Samples of the cellular extracts
nd supernatants from recombinant plasmid transfected cultures
ere submitted to an immunoprecipitation, using the Seize Pri-
ary Immunoprecipitation kit (Pierce Biotechnology Inc.). Brieﬂy,
ml of the cellular extract and 2ml of the supernatant culture was
dded to 0.1 vol. of MIAF-DENV-4 and incubated at 4 ◦C for 8h
n constant agitation. After incubation, 0.1 vol. of Sepharose Pro-
ein A was added to precipitate the antigen–antibody complex,
nd incubated at 4 ◦C for 16h. After incubation, the complexes
ere recovered by centrifugation at 12,000× g for 30 s at 4 ◦C,
ashed 3 times with PBS, suspended in load buffer and submitted
o SDS-PAGE. Following SDS-PAGE, the proteins were transferred
o a nitrocellulose membrane and were visualized by an western
lot assay. In summary, after protein transfer, the nitrocellulose
as blocked for 4h with PBS Tween-20 albumin 5%; the mem-
rane was washed 3 times with PBS Tween-20 and incubated for
h at room temperature with DENV-4 MIAF (1:100). The mem-
rane was then washed and incubated for 2 more hours with
lkaline phosphatase conjugated anti-mouse IgG (Sigma, Saint
ouis, MO). Finally, the membrane was washed 3 more times
ith PBS-Tween-20, stained with the Western Blue Substrate
or Alkaline Phosphatase Kit (Promega, Wiscosin), and correct
rM/E protein expression was deﬁned according to the molecular
eight control.
.6. Immunization of mice
DENV-4-DNAv was prepared with EndoFree Plasmid Mega Kit
QIAGEN) as speciﬁed by themanufacturer. Ten 5-week-old female
ALB/c mice per immunization group were inoculated three times
nto the quadriceps muscle with 100g of DENV-4-DNAv or pCI
empty vector), DENV-4 heat inactivated (1×105 PFU), or PBS. The
ice were primed on day 0 and boosted 15 and 30 days after the
nitial inoculation. Blood samples were obtained right before each
oost and 15 days after the last inoculation. Sera from these mice
ere stored at −70 ◦C until use.
.7. Plaque reduction neutralization test (PRNT)
Pooled mouse sera were also assayed for DENV-4 (H-241 strain)
eutralizing antibody in a plaque-reduction neutralization test
PRNT) slightly modiﬁed from that previously described by Rus-
ell and Nisalak in 1967 [21]. Shortly, DENV-4 stock was serially
iluted in1Xsterile PBS (10-folddilutions) and titratedonduplicate
ells of conﬂuent Vero cell monolayers grown in 12-well plates.
erum samples were heat inactivated at 56 ◦C for 30min, serially
iluted in 1X PBS (1:2–1:256), and then incubated overnight at 4 ◦C
ith an equal volume of a DENV-4 dilution containing approxi-
ately 30 plaque-forming units/ml (pfu/ml). As a control, we used
he same virus preparation mixed with uninfected mouse serum.
he virus–antibody mixes were inoculated on conﬂuent Vero cell
onolayers and after virus adsorption, monolayers were washed
ith PBS, overlaid with 2.0ml of 3% carboxymethylcellulose-L15
verlay medium containing 2% fetal calf serum (FCS), and incu-
ated at 37 ◦C/5%CO2 for 7 days. Cells were then stained with 2%
eutral red to determine the number of plaque forming units per
ilution. The number of plaques reported for each serum dilution29 (2011) 831–838 833
was the average of the duplicate wells. The percentage of plaque
reduction was calculated for each dilution of tested sera using the
number of plaques obtainedwith normalmouse serum at the same
dilution as the baseline control. The highest serum dilution that
reduced in at least 50% the number of plaques was considered the
ﬁnal neutralization titer.
2.8. ELISA quantiﬁcation of IFN- , IL-2, and IL-10 produced by
virus-stimulated lymphoid-cells
Lymphoid spleen cells from immunized and control mice
were collected, washed twice in RPMI 1640 containing 10%
heat-inactivated FBS. After wash, the cells were resuspended at
a ﬁnal concentration of 1×106 cells/ml with RPMI 1640 and
100l aliquots were plated into 96-well culture plates. Then we
added different stimuli to the culture, 1×106 PFU of DENV-4
(heat inactivated) as speciﬁc stimulus or concanavalin A 2g/ml
(Sigma–Aldrich) as mitogenic stimulus, the plates were covered
and incubated at 37 ◦C in a 5% CO2 atmosphere. After 48h of
stimulation, aliquots of supernatants were removed and stored at
−70 ◦C for subsequent analysis. Sandwich-type ELISAs (DuoSetTM,
R&D Systems) were used to estimate the IFN-, IL-2 and IL-10
levels in virus-stimulated and control cell supernatants, accord-
ing to the manufacturer’s instructions. Brieﬂy, serial dilutions
of cytokine standards, samples and controls were added to 96-
well ELISA microplates coated with speciﬁc monoclonal antibody
and incubated for 2h at room temperature. Plates were then
washed ﬁve times with PBS/T (PBS/0.5% Tween) and 100l of
horseradish peroxidase-linked polyclonal anti-mouse antibody
was added. After 2h at room temperature, the plates were washed
ﬁve times and 100l of a substrate solution were added to each
well. The plates were incubated for 30min at room temperature,
and then read at 450nm. The levels of cytokines in the super-
natants were calculated by comparing their O.D. to a standard
calibration curve.
2.9. T cell proliferation assay
The DENV-4 speciﬁc lymphoproliferative responses from vac-
cine and control immunized mice were determined by standard
CFSE staining in two different experiments. Spleens were har-
vested from the same mice (4 mice per group) inoculated with
recombinant DENV-4-DNAv, inactivated DENV-4, and pCI, as pre-
viously described in the Imunization of mice heading. Spleen cell
suspensions were treated with Tris-buffered ammonium chlo-
ride to eliminate the red blood cells, washed, and resuspended in
RPMI 1640 supplemented with 5% FBS, HEPES buffer, l-glutamine,
penicillin and streptomycin. Cells were cultured in triplicate in 96-
well microtiter plates (1×105 cells/well) in the presence of heat
inactivated DENV-4 (1×105 PFU), control RPMI medium, or ConA
2g/ml. Speciﬁc T cell proliferation of DENV-4-DNAv-immunized
mice and control groups were evaluated by staining the cells with
5-(and-6) carboxy-ﬂuorescein diacetate, succinimidyl ester (CFSE)
(Molecular Probes, Oregon, USA). The reading was performed after
3 days of stimulus in a ﬂow cytometry (FACscan) with software
Cellquest (both fromBecton-Dickinson ImmunocytometrySystems
Inc., San Jose, CA), and the statistical analysis was accomplished
using the program WinMDI version 2.8.
2.10. Mouse challenge with DENV-4Groups of ten 3-week-old female BALB/c mice were immu-
nizedwith 100g of recombinant DENV-4-DNAv, heat-inactivated
DENV-4 (1×105 PFU), PBS or pCI (100g), separately in a total of
3 doses with 15 days intervals between them. Fifteen days after
the third inoculation, the mice were challenged intracerebrally
834 D.M. Lima et al. / Vaccine 29 (2011) 831–838
F A), transfected with empty pCI plasmid (B) or with DENV-4-DNAv (50g of recombinant
p -4mouse hyperimmune ﬂuid (MIAF) followed by anti-mouse IgG FITC conjugate showed
c tained with DAPI to detect the presence of transfected cells.
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Table 2
Titer of neutralizing antibodies obtained in mice immunized with DENV-4, pCI and
the vaccine candidate DENV-4-DNAv.
Immunogen Titer of neutralizing antibodies
15 days 30 days 45 daysig. 1. Detection of protein expression in HeLa cells infected with dengue-4 virus (
lasmid) by IFA (C). The IFAwas considered positivewhen cells incubatedwith DENV
haracteristic ﬂuorescence. Note that, in the pCI-transfected cells, the nuclei were s
ith a dose of 100LD50 (previously determined), prepared from
DENV-4-infected suckling mouse brain (mouse-adapted H241
train). Mouse mortality was monitored daily for 21 days. The sta-
istical analysis (Long-Rank test, Mantel-Cox) was performed with
raphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA).
. Results
.1. Protein expression of recombinant plasmid
DENV-4-DNAv transfected cells showed positive ﬂuorescence
hereDENV-4-speciﬁcMIAFwasused,which indicates the expres-
ion of the DENV-4 prM and E proteins. In the cells transfected
ith pCI no ﬂuorescence was seen. As positive control we used
ells infected with dengue-4 virus, these cells were incubated with
rimary antibodies (DENV-4 MIAF) and secondary antibody (anti-
ouse IgG) and analyzed in optical microscopy (Fig. 1).
.2. Immunoprecipitation and western blot
The band corresponding to prM and E protein, of approx-
mately 53–54kDa, was clearly visible in the lanes containing
ENV-4-DNAv transfected cell lysates. This band corresponds to
he expected molecular weight of the E protein and was detected
n cell lysates by immunoprecipitation followed by western blot
rom culture infected with dengue-4 virus and transfected with
ecombinant plasmid but not in cultures transfected with empty
CI (Fig. 2).
ig. 2. DemonstrationofDENV-4Eprotein expression inHela intracellular fractions,
nalyzedby immunoprecipitation followedbywesternblot.HeLacellswere infected
Lane 1) with DENV-4 (M.O.I. = 1) or transfected with 50g of DENV-4-DNAv (Lane
). The protein expression was analyzed 72h after transfection. Molecular weight
arker is indicated on the right of the ﬁgure.DENV-4 1:64 1:128 1:256
pCI Not detected Not detected Not detected
DENV-4-DNAv 1:32 1:64 1:128
3.3. Detection of neutralizing antibodies in mice (PRNT)
Neutralizing antibodies is the goal of dengue vaccination; to
evaluate the induction capacity of our constructionweperformed a
PRNT assay, comparing the results with virus immunization that is
associated with induction of high levels of neutralizing antibodies.
As expected, animals immunized with the pCI plasmid did not pro-
duce neutralizing antibodies against dengue-4 virus. On the other
hand, the animals immunized with DENV-4-DNAv produced ris-
ing levels, after each vaccine inoculation, of speciﬁc neutralizing
antibodies against dengue-4 virus. The neutralizing antibody titers
of DENV-4-DNAv immunized group were only one dilution lower
than those titers observed in DENV-4-immnunized mice (Table 2).
Once we detected satisfactory neutralizing antibodies levels after
vaccination, we decided to evaluate the vaccine protection after
challenge with a lethal infection.
3.4. Quantiﬁcation of cytokines produced by virus-stimulated
lymphoid-cells
The spleen cells of DENV-4-DNAv-immunized animals pro-
duced high levels of IL-2, IL-10, IFN- in the presence of ConA
and DENV-4 compared to non-stimulated cells. Cell supernatants
of DENV-4-DNAv-immunized animals showed much higher con-
centrations of IL-10 and IL-2 than IFN-. The same proﬁle was seen
in the cell supernatants of mice immunized with DENV-4. IL-4 was
not detected in any group of immunized mice independent of the
time of supernatant collection (Fig. 3).
3.5. T cell proliferation assay
To address if T cells obtained from DENV-4-DNAv immunized
mice could respond to speciﬁc antigen stimulus, BALB/c mice were
inoculated with 100g of DENV-4-DNAv in the quadriceps muscle
as described in Section 2. Fifteen days after the ﬁnal immuniza-
tion, the mice were sacriﬁced and splenocytes were prepared to
examine the proliferation response. Splenic lymphocytes derived
from DENV-4-DNAv inoculated group demonstrated high prolifer-
ative response to inactivated dengue virus. Fig. 4 shows the results
obtained in the conﬁrmatory experiment. T cell proliferation in
D.M. Lima et al. / Vaccine
Fig. 3. Cytokine quantitation by ELISA in response to different stimulus observed in
mice immunized with pCI, heat inactivated DENV-4 or DENV-4-DNAv. Splenocytes
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obtainedafter theﬁnal immunizationwitheach immunogen (“x”axis)werecultured
n thepresenceofdifferent stimuli and the supernatant collectedafter 3days.Media:
PMImedia;ConA: concanavalinA2g/ml;DENV-4:1×106 PFUofheat inactivated
ENV-4. These data are representative of 4 animals.
he DENV-4-DNAv group was approximately 20%, similar to that
bserved in DENV-4 immunized group, suggesting that our vaccine
nduced a good cellular immune stimulation. In addition, prolif-
ration responses of DENV-4-DNAv group were higher than that
bserved in the negative control. The results in Fig. 4 are repre-
entative of four animals per group, but in both experiments all
ouse-inoculated groups responded in a similar fashion.
.6. Post-challenge protection
DENV-4-DNAv vaccine candidate was evaluated for their abil-
ty to induce protective immunity against lethal challenge with
ENV-4. Groups of 10 three-week-old BALB/c mice were immu-
ized with recombinant plasmid, positive and negative control
ice were immunized with DENV-4 (1×105 PFU) and with 100g
f pCI, respectively. As shown in Fig. 5, immunization with DENV-29 (2011) 831–838 835
4-DNAv induced signiﬁcant protection against DENV-4 challenge,
comparable to that observed in DENV-4 inoculated mice, where
80% of the challenged mice survived. However, only 20% sur-
vival was observed after immunization with pCI and no survival
was obtained with PBS immunization. The protection levels of
the immunized group was statistical signiﬁcant (p=0.01), when
thisgroupwascomparedwithpCI immunizedanimals (Mantel-Cox
statistical analysis).
4. Discussion
Dengue is responsible for the highest mortality and morbidity
rates than any other disease caused by an arbovirus in humans [22].
Annually, more than 100 million cases of dengue fever and about
500,000casesofDHFoccur, andsince there isno treatment for these
diseases, immunizationmayprovide themost realistic approach for
controlling dengue infections [1,2]. The efforts for the development
of vaccines against to dengue began more than 50 years ago, when
serious cases of the disease were recognized, and since the 1970s
the World Health Organization has sponsored several studies to
obtain these vaccines [23,24]. A recombinant DNA vaccine is a new
approach consisting of a plasmid backbone and the gene encod-
ing the antigen of interest, and it is considered efﬁcient due to the
fact that it elicits both, the humoral and cellular immune responses.
DNA vaccines have been tested in a series of animalmodels, includ-
ing experimental infections inmice and primates [20,25]. Recently,
there has been a remarkable effort on the development of DNA vac-
cines because they are safe, induces fewer side effects than the live
attenuated vaccines, can be administered to immunocompromised
individuals, are cheap to manufacture, and need low infrastructure
for maintenance [26]. Concerning their ability to elicit a suitable
immune response against dengue, there is no doubt that DNA vac-
cines work efﬁciently; since they have been shown to induce both
antibody and T-cell responses, as well as protective immunity, in
numerous animal models [5].
DENV-4 envelope protein (E) was chosen to be a constituent
of our DNA vaccine due to the fact that it contains the main Fla-
vivirus neutralizing epitopes, playing a fundamental role in the
immunity against dengue viruses. Furthermore, other researchers
have included a portion or thewhole E protein in their construction
[27–31]. For instance, Mota et al. [30] showed that the domain III of
the E protein expressed by a tetravalent DNA vaccine formulation
induced neutralizing antibodies and protection against the dengue
virus. We have also included the gene encoding the prM protein in
our construct due to the fact that prMstabilizes theprotein Eduring
the post-translation modiﬁcation process [32]. Therefore, domain
III has been considered the principal candidate target for recombi-
nant vaccines and has been cloned in several different expression
systems togenerate subunit vaccine candidates. Suchproteins elicit
varying levels of virus-neutralizing antibodies [33,34].
In fact, Jimenez and da Fonseca [31] demonstrated the impor-
tance of prM protein on the correct processing of E protein, by
manufacturing a DENV-2 DNA vaccine lacking the prM gene. A low
survival rate (20%) was observed with this construction, possibly
because of the weak activation of the immune system resulting
from an imperfect processing of the E protein, due to the absence
of prM protein [31]. Furthermore, the neutralizing epitopes of
the E protein against dengue viruses seem to be conformation
dependent, and studies with dengue viruses and other Flavivirus
demonstrate that the correct conformation of E protein is asso-
ciated with the co-expression of prM protein [28,29,32,35]. In
another study of our group a dengue-3 DNA vaccine was con-
structed, using the same strategy. The prM and E genes of dengue-3
virus were inserted in pCI vector and the immune response was
evaluated. The results showed good levels of protection in mice
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big. 4. T cell proliferation responses to different stimuli observed in mice inoculated
mmunization with each immunogen (bold title) were tested by a CFSE assay. The sp
f DENV-4 heat inactivated; ConA: concanavalin A 2g/ml.M2: percentage of cells t
mmunized with this vaccine (80%) and detectable levels of neu-
ralizing antibodies [27]. Probably the satisfactory levels of protein
xpression and protection in mice found with DENV-3 vaccine, has
eenassociatedwith the inclusionofprMgene in theplasmid.Here,
ur intention was to construct another DNA vaccine employing the
ame strategy. We selected dengue virus type 4 and after plasmid
onstructionweevaluatedprotein expression and immunogenicity
f this construct. The correct expression of E protein by DENV-4-
NAv was accessed in vitro. Expression was detected by sandwich
LISA, indirect immunoﬂuorescence assay, and immunoprecipita-
ion followed by western blot as demonstrated. Once the correct
xpression of E protein in eukaryotic cells transfected with DENV-
-DNAv was detected (in vitro assays), in vivo immunogenicity
f DENV-4 plasmid construct was evaluated in BALB/c mice. To
ddress the protector potential of our vaccine candidate, the ani-
als were immunized and the speciﬁc immune response elicited
gainst the dengue-4 virus was investigated.
DENV-4-DNAv immunized animals produced neutralizing anti-
odies against the DENV-4 and survived after challenge with apCI, heat inactivated DENV-4 or DENV-4-DNAv. Splenocytes obtained after the ﬁnal
stimuli were showed in each histogram. Media: RPMI media; DENV-4: 1×105/PFU
oliferated from3 days after the stimulus. These data are representative of 4 animals.
lethal dose of DENV-4, even with low titer of detectable neutral-
izing antibodies that we observed in our groups. These data are in
agreement with the work conducted by Putnak et al. [36], where
immunized mice also developed low titers of neutralizing anti-
bodies. The researchers immunized BALB/c mice with 100g of
a DNA vaccine (pcDNA3JEME), which did not induce high levels of
neutralizing antibodies, but protected the animals after challenge
with a lethal dose of the Japanese Encephalitis virus [37]. Low titers
of neutralizing antibodies in mice immunized with DNA vaccines
expressing dengue virus prM/E protein have been also observed
by other researchers. Konishi et al. [35] reported neutralizing anti-
body titers of 1/10 after three immunizations with 100g of DNA
expressing DENV-2 prM/E protein. Another study conducted by
Raviprakash et al. [37] detected a titer of 1/40 after 3 immuniza-
tions with 100g of DNA expressing DENV-1 prM/E protein. The
antibody titers against DENV-4 in this study is higher than those
observed in other studies, even though there has been only a hand-
ful of studies aiming at thedevelopment of aDNAvaccine candidate
to DENV-4. In a general view there is not a consensus of minimum
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Fig. 5. Survival percentage of immunized mice after challenge with DENV-4.
Groups of 3-week-old female BALB/c mice (n=10) immunized with DENV-4-DNAv,
DENV-4 heat inactivated, PBS or pCI, were challenged with 100LD50 of DENV-4
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Castan˜eda B, Rojo-Domínguez A, García-Cordero J, et al. A plasmid encodingnd monitored daily for survival up 21 days post-challenge, *p=0.01 in DENV-4-
NAv compared with pCI immunized group (Log-Rank test, Mantel-Cox statistical
nalysis).
evels of neutralizing antibodies correlatedwithdengueprotection.
owever, Guirakhoo et al. [8] reported that low antibody titers
etween 20 and 80 were protective against dengue challenge. In
ur attempt with dengue-3 DNA vaccine the levels of neutralizing
ntibodies were lower than virus immunized group, but the ani-
als showed increased survival rate [27]. In conclusion,we showed
hat the neutralizing antibodies titer described here is sufﬁcient to
nduce a good protection against dengue-4 infection in mice, as
emonstrated by challenge assay.
We evaluated T cell response bymeasuring cytokine levels (IFN-
, IL-2 and IL-10) and cell proliferation by CFSE staining. Cytokines
ere measured in the supernatant of stimulated spleen cells of
ENV-4, DENV-4-DNAv, and pCI immunized animals. The impor-
ance of measuring cytokine levels in vaccination studies relies
n the fact that cytokines induce an antiviral state in the host by
ctivating antigen presenting cells, and also playing a part in the
odulation of the cellular and humoral immune response, dur-
ng the course of the infection [38]. Th1 helper cells mediate Th1
esponse characterized by production mainly of IFN-, whereas
h2 response involves the production of IL4 and IL10. In this study,
ENV-4-DNAv vaccine candidate induced a high expression of IL-
0. A study done by Wu et al. [39] evaluated the mechanism of
he immune response induced by a DNA vaccine expressing the
on-structural NS1 protein, and observed that the immunizedmice
esponded preferentially with a Th1 pattern. However, IL-4 was
lso detected providing an evidence for a Th2-mediated immune
esponse. Rothman et al. [40], analyzing a tetravalent inactivated
engue vaccine, also detected high levels IFN-, but no IL-4 after
he stimulation with dengue virus. We suggest that our high levels
f IL-10 can be associated with a Th2 pattern immune response,
t is accepted that this type of response is able to induce a strong
ntibody production. However, we did not evaluate the production
f IgG1 versus IgG2a antibodies and so we cannot conﬁrm the shift
f immune response in favor of Th2 pattern.
The cellular proliferation assay, accessed by ﬂow cytometry,
valuated the activation of spleen cells from mice immunized with
ENV-4-DNAv, DENV-4 (positive control), and pCI (negative con-
rol). Spleen cells of all groups of immunized animals presented
signiﬁcant proliferation in the presence of lymphocyte mito-
en concanavalin A, compared to cells that were not stimulated
media stimulation). When speciﬁcally stimulated with DENV-4,
he spleen cells from DENV-4-DNAv-immunized mice proliferated
n a signiﬁcant higher percentage than cells from pCI-immunized
nimals (negative control) and did not exhibited a signiﬁcant dif-
erence in proliferation compared to the cells of the animals in the
ENV-4-immunized group. Taking together, these data conﬁrmed
hat the DENV-4 and DENV-4-DNAv were capable of inducing a29 (2011) 831–838 837
speciﬁc immune response in the immunized mice. Data on T cell
response after immunization against dengue are scarce, mainly
because most of the studies on dengue vaccine development focus
their search for a speciﬁc immune response on neutralizing anti-
bodies [35].Herewe showapositiveperformanceofDENV-4-DNAv
vaccine concerning its ability to induce speciﬁc T cell response,
antibody production and protection after challenge. The challenge
experiments show that 80% of the mice immunized with DENV-4-
DNAvwere protected from thedisease induced by the intracerebral
inoculation with lethal doses of DENV-4, the same percentage
observed in DENV-4 immunized mice. On the other hand, in pCI
and PBS-inoculated animals, the protection rate was 20% and 0%,
respectively. The observation that 20% of the inoculated mice in
the DENV-4 and DENV-4-DNAv died after challenge despite the
fact that all of them developed neutralizing antibodies might be
explained by the animal model used in dengue vaccine experi-
ments. The animal model most frequently used to test the efﬁcacy
of dengue vaccines during dengue vaccine development is based
in intracerebral inoculation of mice with a mouse-brain-adapted
dengue virus. However, this model does not represent a natural
disease as encephalitis is not commonly associated with dengue
infections. Due to the lack of a good animal model to test dengue
vaccines and to the fact that humans and mosquitoes represent the
only two natural hosts for DENV, it is unrealistic to hope that a
single mouse model will address all the features of dengue patho-
genesis and may account for some unexpected results, such as the
lack of protection of 20% of the immunized mice. Moreover, it is
possible that this animal model and the presence of immunos-
timulatory CpG motifs in the pCI plasmid explain the low level of
non-speciﬁc protection observed in the mouse group immunized
with pCI plasmid [41].
In conclusion, the combination of the results presented here
and the fact that there have been only a few studies investigating
the manufacturing of DNA vaccines against dengue-4 show that
DENV-4-DNAv vaccine candidate represents a promising strategy
to control dengue infections, principally by its ability to induce a
solid immune response against the homologous virus. In the last
years, our group has been working with other dengue subtypes
focusing on a tetravalent vaccine [27,31]. Thus, the good results
obtained here with dengue-4, together with our previous success
with a dengue-3 vaccine DNA vaccine, allow this vaccine candidate
to be hereafter tested in a tetravalent formulation against dengue
virus infections.
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